Search Results
Your search for The ASCO ,The ASCO matches 21410 pages
Showing 101 - 150Study Reports Increasing Incidence Rates of Appendiceal Adenocarcinoma in Those Born After 1945
A recent study published in the Annals of Internal Medicine1 estimated incidence rates of appendiceal adenocarcinoma across birth cohorts in the United States. Andreana N. Holowatyj, PhD, MSCI, of Vanderbilt-Ingram Cancer Center, Nashville, and colleagues observed a sharp increase in incidence...
MRD-Guided Treatment in Newly Diagnosed Multiple Myeloma
In a French-Belgian phase III trial (MIDAS) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Perrot et al examined the outcomes of treatments guided by measurable residual disease (MRD) status in patients with newly diagnosed multiple myeloma. Study Details In...
Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
In a phase III trial (C-POST) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Rischin et al compared disease-free survival outcomes of adjuvant cemiplimab vs placebo in patients with high-risk cutaneous squamous cell carcinoma. Study Details In the trial, 415...
Self-Collection Kit Mailings May Increase Cervical Cancer Screening Rates in Underserved Settings
Mail-in self-collection kits for human papillomavirus (HPV) were found to be effective at increasing cervical cancer screening rates compared with standard telephone reminders alone in a safety-net health-care setting, according to results from the PRESTIS trial published in JAMA Internal Medicine. ...
Low-Value Cancer Screenings May Continue for Years Following Guideline Change to Limit Unnecessary Tests
Stopping the widespread use of unnecessary, potentially harmful cancer screenings may take up to 13 years and potentially longer following the implementation of new guidelines, according to a recent study published by LeLaurin et al in BMJ Quality & Safety. Background The U.S. Preventive...
AACR Statement on Former President Joseph Biden’s Cancer Diagnosis
The American Association for Cancer Research (AACR) has issued the following statement regarding former President Joseph R. Biden’s prostate cancer diagnosis: “The American Association for Cancer Research (AACR) offers heartfelt support and well wishes to former President Biden and his family as...
I Was an N-of-1 in a CAR T-Cell Therapy Trial for Ovarian Cancer
More than a decade after I was diagnosed with late-stage ovarian cancer, a phase I clinical trial at Moffitt Cancer Center and Research Institute in Tampa, Florida, investigating a dose of a novel follicle-stimulating hormone receptor (FSHR)-targeting chimeric antigen receptor (CAR) T-cell therapy...
MD Anderson Names Jeffrey E. Lee, MD, Chief Medical Executive
The University of Texas MD Anderson Cancer Center announced that Jeffrey E. Lee, MD, an internationally regarded leader in the field of oncology, has been appointed Chief Medical Executive (CME). Prior to his appointment, Dr. Lee served as CME ad interim. Assuming the role of CME is the...
Use of Bispecific Antibody in Older Patients With Relapsed or Refractory Multiple Myeloma
Although treatment with the bispecific antibody teclistamab was approved for patients with relapsed or refractory multiple myeloma, based on the MajesTEC-1 study results, only 15% of patients in the phase I/II trial were aged 75 or older. To learn more about the safety and efficacy of this agent in ...
ESTRO 2025: Major Advances in Radiotherapy for Anal and Rectal Cancers
In May in Vienna, five studies presented at ESTRO (European Society for Radiotherapy and Oncology) 2025 showcased how radiotherapy is reshaping the landscape for anal and rectal cancers. From reduced-dose treatments to cutting-edge combinations with immunotherapy and chemotherapy, these innovations ...
Why Black Women Have a Higher Risk of Dying of All Types of Breast Cancer Than White Women
The disparities in breast cancer incidence and mortality rates between Black and White women in the United States have been well documented. Studies over the past decade consistently show that although Black women have a 4% lower breast cancer incidence rate than White women, they are still between ...
ASTRO Survey Data Illustrate Impact of Continued Medicare Cuts on Cancer Care
Recent national survey data from the American Society for Radiation Oncology (ASTRO) have shown that further cuts to Medicare reimbursement for radiation therapy would increase patient wait times for cancer treatment and force clinic downsizing. Nearly all (96%) of the 675 physicians responding to...
Retifanlimab-dlwr Approved for Anal Cancer in Combination With Carboplatin Plus Paclitaxel and as a Single Agent
The U.S. Food and Drug Administration (FDA) approved retifanlimab-dlwr (Zynyz), a PD-1–blocking monoclonal antibody, with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. The FDA also...
Expanded Treatment Options for Metastatic CRPC: ASCO Guideline Addresses Somatic Genetic Testing, Radiopharmaceuticals
The management of metastatic (CRPC) has rapidly accelerated in the past decade, giving oncologists a wider range of tools to work with and patients new opportunities for improving survival and maintaining quality of life. These significant advancements have prompted ASCO to release a guideline...
How the Elimination of Federal Gender-Related Grants and DEI Programs Is Impacting LGBTQ+ Health Research
Within hours of the start of his second administration, on January 20, 2025, President Donald Trump signed an executive order proclaiming that the country would now recognize only two sexes, male and female, essentially rejecting transgender identity, and directing all federal agencies to use the...
Improving the Alliance Between Oncologists and Primary Care Providers: A Call for Collaborative Action
Experts and patients alike would agree that navigating the current fragmented U.S. health-care system is not an easy task. One component of that disconnection may center on the relationship between oncology and primary care. The benefits of collaboration between oncologists and primary care...
Study Shows Potential Benefits of AI-Assisted Classification in HER2-Low and HER2-Ultralow Breast Cancer
With the approval of HER2-targeted antibody-drug conjugate options for treating patients with breast cancer across different HER2 expression levels, accurate assessment of HER2 expression has become more important than ever. And a recent study may provide a solution to the challenge of accurate...
Structured Exercise Program Improves Survival Outcomes in Patients With Stage III or High-Risk Stage II Colon Cancer
A 3-year structured exercise program initiated soon after completion of adjuvant chemotherapy improved disease-free survival and overall survival, as well as patient-reported physical functioning and health-related fitness, in patients with stage III or high-risk stage II colon cancer. These...
Study Finds GLP-1RAs May Lower Risk of Obesity-Related Cancers vs DPP-4 Inhibitors in Adults With Diabetes and Obesity
Studies have shown that being overweight or having obesity increases the risk of developing more than a dozen cancers, including meningioma, multiple myeloma, esophageal, thyroid, breast, gallbladder, stomach, liver, pancreas, kidney, ovarian, uterus, and colorectal.1 The presence of excess body...
Maintenance Therapy With Lurbinectedin Plus Atezolizumab Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer
Maintenance treatment with the alkylating agent lurbinectedin plus the monoclonal antibody atezolizumab significantly improved both progression-free survival and overall survival compared with atezolizumab alone in patients with extensive-stage small cell lung cancer (SCLC), according to data...
Overall Survival Benefit Achieved With Inavolisib Plus Palbociclib and Fulvestrant in Advanced Breast Cancer
“Inavolisib plus palbociclib and fulvestrant significantly improved overall survival compared with placebo plus palbociclib/fulvestrant…. This is the first time overall survival has been significantly improved by a PI3K pathway–targeted drug,” said Nicholas Turner, MD, PhD, FRCP,FMedSci, who...
Inherited Genetic Differences May Predict Resistance to Immunotherapy in Metastatic Melanoma
Researchers may have uncovered genetic differences that may help predict response to immune checkpoint inhibitors among patients with metastatic melanoma, according to a recent study published by Monson et al in Nature Medicine. Background The investigation revolved around mitochondrial haplogroups ...
Use of Adjuvant Aspirin Reduces the Risk of Recurrence in PI3K-Mutated Colorectal Cancer
In the phase III ALASCCA trial, the use of adjuvant daily aspirin for 3 years reduced the risk of recurrence in colorectal cancer harboring PI3K pathway alterations by 51%, according to research in a Scandinavian population presented at the 2025 ASCO Gastrointestinal Cancers Symposium by Anna...
Cancer May Be Detectable in Bloodstream 3 Years Prior to Diagnosis
Genetic material shed by tumors may be detected in the bloodstream 3 years prior to cancer diagnosis, according to a recent study published by Wang et al in Cancer Discovery. Study Methods and Results Researchers used highly accurate and sensitive sequencing techniques to analyze the plasma samples ...
Ruben A. Mesa, MD, on Essential Thrombocythemia: SURPASS-ET Trial
Ruben A. Mesa, MD, of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, presents results from a phase III trial investigating the efficacy of ropeginterferon alfa-2b vs anagrelide for the treatment of essential thrombocythemia (Abstract 6500). ...
Violaine Randrian, MD, PhD, on Lynch Syndrome, Genetics, and Immunotherapy
Violaine Randrian, MD, PhD, of Memorial Sloan Kettering Cancer Center and CHU/Université de Poitiers, reviews gene-specific outcomes in patients with Lynch syndrome treated with immune checkpoint inhibitors for advanced cancer (Abstract 10504).
ACS CAN Statement on Federal Cuts to Cancer Research
On May 30, President Donald Trump released his final proposed budget for Fiscal Year 2026, which contains $4.531 billion for the National Cancer Institute (NCI). This represents a cut of almost $2.7 billion, or approximately 37.2%, from the current fiscal year. The following is a statement from...
Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy
Hope S. Rugo, MD, FASCO, of City of Hope, and Rebecca Alexandra Dent, MD, FASCO, of National Cancer Centre Singapore, review the results of a biomarker analysis of the DESTINY-Breast06 trial, which evaluated trastuzumab deruxtecan after endocrine therapy in patients with metastatic breast cancer...
Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs
Neil M. Iyengar, MD, of Memorial Sloan Kettering Cancer Center, reviews several studies that aimed to answer two questions: does menopausal hormone therapy (HRT) impact overall survival and breast cancer–specific mortality in younger women diagnosed with high-risk disease (Abstract 10506); and do...
Eric Huttenlocher Bent, MD, PhD, on Oligometastatic Prostate Cancer: Intensified Hormonal Blockade
Eric Huttenlocher Bent, MD, PhD, of Memorial Sloan Kettering Cancer Center, reviews results from the phase II Metacure trial (cohorts B2 and the B2 expansion), which looked at the efficacy of stereotactic body radiotherapy for PSMA-PET–detected oligometastatic prostate adenocarcinoma (Abstract...
Praful Ravi, MBBChir, MRCP, on High-Risk Localized Prostate Cancer: Docetaxel With ADT and Radiotherapy
Praful Ravi, MBBChir, MRCP, of Dana-Farber Cancer Institute, presents findings from an ICECaP individual patient-data meta-analysis of randomized controlled trials on a treatment strategy used in high-risk localized prostate cancer (Abstract 5013).
Treatment for Intractable Cancer Pain Pioneered
A novel therapy based on the plant-derived molecule resiniferatoxin could be a safe and effective agent for patients with difficult-to-control cancer pain, according to a recent study published by Mannes et al in NEJM Evidence. Background Resiniferatoxin is derived from Euphorbia resinifera, a...
Suneel Deepak Kamath, MD, on Disparities in NIH and Federal Funding Across Different Cancer Types
Suneel Deepak Kamath, MD, of the Cleveland Clinic, reports findings from a study that evaluated funding from the NIH and Congressionally Directed Medical Research Programs supporting lung, breast, colorectal, pancreatic, hepatobiliary, ovarian, cervical, endometrial, and prostate cancers, as well...
Are Most Americans Aware of the Link Between Alcohol and Cancer Risk?
Although alcohol consumption is a known leading preventable cause of cancer, public awareness of the connection may remain concerningly low in the United States, according to a recent study published by Domgue et al in JAMA Oncology. Background Consuming alcohol has been linked to at least seven...
Luis G. Paz-Ares, MD, PhD, on Extensive-Stage SCLC: Comparison of First-Line Regimens
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, discusses data from the TIGOS trial, a phase III study comparing the first-line use of atigotatug (an antifucosyl-GM1 monoclonal antibody) plus nivolumab fixed-dose...
Luis G. Paz-Ares, MD, PhD, on IMforte Trial in Extensive-Stage SCLC
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, presents primary results from the phase III IMforte trial, which evaluated lurbinectedin plus atezolizumab as first-line maintenance treatment in patients with...
Nitin Jain, MD, on Front-Line Therapies for CLL: Research Highlights From ASCO 2025
Nitin Jain, MD, Professor in the Department of Leukemia and Director of the Leukemia CAR-T Program at The University of Texas MD Anderson Cancer Center, shares his expert point of view on data presented on front-line therapies for chronic lymphocytic leukemia (CLL) presented at the 2025 ASCO Annual ...
Novel Antibody-Drug Conjugate for Newly Diagnosed BPDCN
The first-in-class antibody-drug conjugate pivekimab sunirine was found to be safe and effective, with high response rates, in patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a phase I/II study presented at the 2025 ASCO Annual Meeting (Abstract 6502). These ...
FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer
On June 3, 2025, the U.S. Food and Drug Administration (FDA) approved darolutamide (Nubeqa) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). The oral androgen receptor inhibitor had previously been approved by the FDA in combination with docetaxel for mCSPC. Efficacy...
SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC
Although the SWOG S2302 Pragmatica-Lung trial did not achieve its primary endpoint of improved overall survival with the combination of ramucirumab and pembrolizumab compared with standard-of-care treatments for patients with stage IV or recurrent non–small cell lung cancer (NSCLC) who previously...
Early Driver of Lineage Plasticity in Prostate Cancer Cells
Researchers have identified a gene that could play a key role in the transition to a more aggressive, treatment-resistant type of prostate cancer, according to a recent study published by Duan et al in the Journal of Clinical Investigation. The findings indicated that the gene may be indirectly...
Preoperative THP Leads to pCR in Two-Thirds of Patients With Early-Stage HER2-Positive ER-Negative Breast Cancer
Patients with stage II and III (early-stage) HER2-positive breast cancer usually undergo preoperative therapy with multiagent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A less intensive, reduced-chemotherapy treatment approach is currently being evaluated in the...
Ciltacabtagene Autoleucel Delivers Lasting Remissions in Relapsed or Refractory Multiple Myeloma
New long-term follow-up data from the phase Ib/II CARTITUDE-1 study demonstrated that one-third of patients in the study with relapsed or refractory multiple myeloma treated with the chimeric antigen receptor T-cell therapy ciltacabtagene autoleucel achieved progression-free survival of 5 years or...
Anti-Inflammatory Diet Could Benefit Survival Following Stage III Colorectal Cancer
Consuming an anti-inflammatory diet could improve posttreatment survival among patients with colorectal cancer compared with following a proinflammatory diet, according to new findings presented by Char et al at the 2025 ASCO Annual Meeting (Abstract LBA3509). The findings suggested that engaging...
Novel Dual-Target CAR T-Cell Therapy May Slow Growth of Recurrent Glioblastoma
An investigational dual-target chimeric antigen receptor (CAR) T-cell therapy approach could slow tumor growth in patients with recurrent glioblastoma, according to new findings presented by Bagley et al at the 2025 ASCO Annual Meeting (Abstract 102) and simultaneously published in Nature ...
EMR-Integrated Messaging Drastically Increases Cancer-Related Fertility Preservation Referrals
The integration of a "best practice advisory" alert into electronic medical record system regarding referrals for fertility preservation programs for young patients with cancer improved referrals to the Oncofertility program at Fox Chase Cancer Center by 450% over 6 months, according to findings...
Shahzad Raza, MD, on Relapsed or Refractory AL Amyloidosis: First U.S. Trial of CAR T-Cell Therapy
Shahzad Raza, MD, of the Cleveland Clinic, reviews safety and efficacy data from Nexicart-2, the first U.S.-based trial of chimeric antigen receptor (CAR) T-cell therapy—an agent known as Nxc-201—in patients with relapsed or refractory light chain (AL) amyloidosis (Abstract 7508).
Jamie E. Chaft, MD, FASCO, on Resectable EGFR-Mutated NSCLC: NeoADAURA Results
Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, reviews results of the NeoADAURA trial, which looked at neoadjuvant osimertinib with or without chemotherapy vs chemotherapy alone in patients with resectable EGFR-mutated non–small cell lung...
Bjorn Henning Gronberg, MD, PhD, on SCLC: Adjuvant Immunotherapy After CRT
Bjorn Henning Gronberg, MD, PhD, of Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital, presents phase II findings on the efficacy of atezolizumab after chemoradiotherapy (CRT) in limited-stage small cell lung cancer (SCLC) (LBA8005).
Nicholas D. James, PhD, FRCP, MBBS, on Using AI to Identify Benefit From Prostate Cancer Therapy
Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, describes the use of a multimodal artificial intelligence (AI) model to identify benefit from second-generation androgen receptor pathway inhibitors in patients with high-risk...
